Novo Nordisk A/S
Stocks making the biggest moves midday: Alphabet, Disney, Arista Networks, Super Micro and more
Check out the companies making headlines in midday trading. Alphabet — The tech behemoth fell 8%. Eddy Cue, senior vice president of services at Apple, said on Wednesday that Apple was “actively looking at” reshaping its Safari web browser to focus on AI-powered search functions, according to a Bloomberg report . Cue made the comments […]
Read More
Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won’t derail Eli Lilly’s obesity market dominance
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Despite […]
Read More
Stocks making the biggest moves premarket: Disney, Super Micro, Novo Nordisk, Uber and more
Check out the companies making headlines in premarket trading. Disney — Shares of the media and entertainment company advanced more than 7% after surpassing Wall Street’s second-quarter estimates. Disney reported adjusted earnings per share of $1.45 on revenue of $23.62 billion, while analysts polled by LSEG were looking for $1.20 per share and $23.14 billion, […]
Read More
European markets edge lower as corporate earnings remain in focus; Novo Nordisk jumps 4%
German factory orders jumped more than expected in March ERGOLDING, GERMANY – OCTOBER 25: An employee during the final check while Bavarian Minister of State Florian Herrmann attends the opening of the new electric car motor housing production line at the BMW Landshut factory on October 25, 2024 in Ergolding, Germany. Analysts are predicting a […]
Read More
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk on Wednesday reported a better-than-expected rise in […]
Read More
Hims & Hers brings former Amazon executive into C-suite
Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Courtesy: Hims & Hers Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped […]
Read More
Inside the deal: Roche and Zealand Pharma’s $5.3 billion obesity drug gambit
A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” […]
Read More
UK stocks choppy amid best run in 8 years; Novo Nordisk jumps 5%
The morning after US President Trump’s announcement of European and worldwide trade tariffs, which included a 10% levy for imported goods from the UK, shoppers spend on Oxford Street beneath union jack flags in London’s West End, on 3rd April 2025, in London, England. Richard Baker | In Pictures | Getty Images LONDON — The […]
Read More
CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its […]
Read More
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal. The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 […]
Read More